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a high percentage of patients with heritable disorders
as their primary indication for HSCT. The reversal of
this association in patients receiving HSCT from un-
related donors may reﬂect increased disparity of genes
across the major histocompatibility complex between
a recipient and an unrelated donor. HLA-DR15 oc-
curs at a relatively high frequency worldwide (9.91%-
14.35%; 0.5%-54%) [1, 2], which suggests the exis-
tence of several ancestral haplotypes containing this
allele group. Matching ancestral haplotypes, and
hence, genes across the entire major histocompatibil-
ity complex, is guaranteed in related donation. In
unrelated donation, the likelihood of the donor and
recipient sharing an ancestral haplotype is extremely
low. Our data suggests that matching for additional
(non-HLA) genes within the major histocompatibility
complex contributes positively to HSCT outcome,
and further research to identify additional loci of in-
terest may enhance survival in unrelated HSCT.
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Unrelated Stem Cell
Transplantation after a
Reduced Intensity
Conditioning Regimen
Containing High-Dose
Thymoglobulin Leads to
Controllable Graft-
versus-Host Disease
Between April 2001 and November 2004, 28 pa-
tients with acute myeloid leukemia (AML), acute lym-
phoblastic leukemia (ALL), chronic myeloid leukemia
(CML), and myelodysplastic syndrome (MDS) had
allogeneic stem cell transplantation (SCT) from an
unrelated donor after a novel conditioning regimen con-
taining high-dose thymoglobulin (THY) (Table 1).
Fourteen patients had early disease: CML in ﬁrst
chronic phase (n  4), untreated MDS (n  5), or
acute leukemia in ﬁrst remission (n  5). Another 14
patients had advanced disease: CML in accelerated
(n  1), blastic (n  1) or 2nd chronic phase (n  2),
acute leukemia with primary induction failure (n  1),
in ﬁrst relapse (n  1), in 2nd remission (n  6), or in
3rd remission (n  2). All patient/donor pairs were
evaluated at the allele level for DRB1, but only 16 of
28 pairs had high-resolution typing for human leuko-
cyte antigen (HLA) class I antigens. With the tests
performed, 13 patient/donor pairs (46.4%) had HLA
antigen and/or allele mismatches, which are discrim-
inated in Table 1. Of the 7 females that donated, only
1 had a history of 2 previous pregnancies, whereas all
the others had not been pregnant. The patients trans-
planted with bone marrow received a lower cell dose
than the recipients of peripheral blood progenitor
cells (PBPC) (Table 1). The conditioning regimen
consisted of Ara-C 2 g/m2 on day 8, ﬂudarabine 30
mg/m2/day on days 8 to 4, THY 5 mg/kg/day
(Genzyme-Sangstat, Lyon, France) on days9 to5,
and melphalan 70 mg/m2/day on days 3 and 2.
Although THY was scheduled to be administered as a
12-hour infusion, 26 of 28 patients received the
planned dose over 24 hours because of toxicity. All
patients received prophylactic clemastine and pred-
nisolone 2 mg/kg/day on days 9 to 5 (1 mg/kg
prior to the administration of THY and 1 mg/kg in
the bag with THY), as previously described [1].
Patients with signiﬁcant THY toxicity also received
intravenous ranitidine. Graft-versus-host-disease
(GVHD) prophylaxis consisted of mycophenolate
mofetil 1 g every 12 hours plus cyclosporine A at
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therapeutic levels. A signiﬁcant number of patients
had cyclosporine A discontinued early posttrans-
plant: 12 patients on day 60, 3 patients on day 75,
and 2 patients on day 120. Mycophenolate mofetil
was stopped between days 120 and 180 posttrans-
plant.
The major side effect of 25 mg/kg THY was
high fever, occurring in 13 patients. The second
most frequent side effect was a cutaneous rash,
developing in 8 patients, followed by hypotension in
7 cases. Finally, 4 patients had diarrhea, in 1 case
severe, and 2 patients had transitory shortness of
breath. All of these events were easily managed in
the transplant unit with antihistamine drugs and
steroids, and only 1 patient with hypotension re-
quired dopamine administration. All 28 patients had
prompt engraftment (Table 1). The median day for
the ﬁrst febrile episode was day 5 (day 8 to day
15), the patients received a median of 28 days of
broad spectrum intravenous antibiotics and 11 pa-
tients were treated with liposomal amphotericin B
for presumed or proved invasive fungal infection.
The major infectious complication posttransplant
was cytomegalovirus (CMV) reactivation, which oc-
curred in 12 of the 28 patients. The probability of
transplant-related mortality (TRM) at 1 year was
18.3%  7.4% (data not shown). Overall, 14 patients
died because of relapse (n 4), interstitial pneumonia (n
 4), of which 2 had CMV reactivation, multiple
organ failure (n  3), acute GVHD (n  1), sepsis (n
 1), and Epstein-Barr virus induced donor-derived
B cell lymphoma (n  1). Acute GVHD developed
in 14 of 28 patients: grade I (n  9) and grades II to
IV (n  5). The 5-year probability of acute GVHD
was 33.1%  9.7% (Figure 1A). Chronic GVHD
developed in 10 patients, which was limited in 6 pa-
tients and extensive in the other 4, of which 2 had
moderate severity: bronchiolitis obliterans (n 1) and
scleroderma-like disease (n  1). The probability of
chronic GVHD (limited and extensive) at 5 years was
44.6%  12.8% (Figure 1A). The 5-year incidence of
relapse was 25.8%  10.4% (data not shown), which
was higher in patients without any form of GVHD
(44.4%  16.5% versus 14.3%  13.2%, P  .01)
(data not shown). As of June 30, 2006, 14 of 28
patients were alive with a median survival time of 865
days. The Kaplan-Meier estimate of overall survival
(OS) and disease-free survival (DFS) at 5 years for the
whole group is 48.7%  9.7% and 45.4%  9.6%,
respectively (data not shown). Patients with early dis-
ease had a superior 5-year OS and DFS than those
with advanced disease (OS, 71.4%  12.0% versus
23.8%  12.9%, P  .001; DFS, 64.3%  12.8%
versus 23.8%  12.9%, P  .02) (data not shown).
The patients with limited or extensive chronic GVHD
had a signiﬁcantly superior probability of OS and DFS
at 5 years than those without this complication (OS,
88.9%  10.5% versus 40.0%  13.9%, P  .02;
DFS, 88.9%  10.5% versus 34.3%  13.0%, P 
.01) (Figure 1B).
We used high-dose THY because when accrual
began in 2001 most of our patient/donor pairs were
being HLA-typed at the antigen level with the ex-
ception of DRB1, and we were concerned with the
risk of severe GVHD. In 11 patients, these grafts
came in the form of PBPC, further increasing this
risk. Moreover, we never collected autologous stem
cells and, because we were not using a conventional
conditioning regimen, we wanted to minimize the
risk of graft rejection. The dose of 25 mg/kg THY
is signiﬁcantly higher than the one used in recent
studies [2-5]. It is known that the effect of antithy-
mocyte globulin (ATG) in SCT depends on the
Table 1. Clinical Characteristics
Clinical Characteristics
Patients
Sex: female/male 15/13
Age in years (range) 37.5 (13-52)
CMV IgG positive 23/28
Diagnosis
AML
CR1/CR2/CR3/PIF/Rel 3/4/2/0/1
ALL
CR1/CR2/CR3/PIF/Rel 2/2/0/1/0
MDS 5
CML
CP1/CP2/AC/BP 4/2/1/1
Donors
Sex: female/male 7/21
Age in years (range) 38 (18-51)
CMV IgG positive 15/28
HLA mismatches between
patients and donors
Antigen A 4
Antigen C 4
Antigen C  Allele B 2
Allele B 1
Allele DRB1 1
Allele DQB1 1
Composition of the grafts and
number of cells
Bone marrow (n  17)
Nucleated/CD34 3.27 X 108/kg*/2.60 X 106/kg*
PBPC (n  11)
Nucleated/CD34 8.94 X 108/kg*/4.35 X 106/kg*
Engraftment
Bone marrow recipients
Neut > 0.5†/Plaq > 20†/
Plaq > 50† Day13*/Day 18*/Day 27*
PBPC Recipients
Neut > 0.5†/Plaq > 20†/
Plaq > 50† Day10*/Day 12*/Day 18*
AML indicates acute myeloid leukemia; AP, accelerated phase;
BP, blastic phase; CP, chronic phase; CR, complete remission;
PIF, primary induction failure.
*Median.
†X 109/L.
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product that is used, the dose, and the timing of
administration [6]. If ATG is administered closer to
the day of transplant, a lower dose is necessary, and
some regimens infused the last dose of ATG on the
day of transplant, with very good results [4]. Our
regimen included THY from days 9 to 5, which
can be considered quite early before the transplant
and, to attain the desired effect, a higher dose needs
to be administered [6].
We believe that the incidence of severe acute and
chronic GVHD in our group of patients with known
antigen/allele HLA incompatibilities in 46.4% of the
Figure 1. Probabilities of acute and chronic GVHD were 33.1% and 44.6%, respectively (A); DFS was superior in patients with limited/
extensive chronic GVHD (88.9% versus 34.3%) (B).
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cases was low. Acute grade II-IV GVHD developed in
17.8% of the patients, most cases of chronic GVHD
were limited, and the 4 patients with extensive chronic
GVHD (17.4% of the patients surviving to day 100)
were not severe, did not require prolonged treatment
and never developed serious infections. Other groups
have demonstrated the beneﬁcial effect of THY in
reducing the incidence of acute and chronic GVHD
after unrelated SCT [2-5,7]. With a median follow-up
similar to our study, the GITMO group showed a
39% incidence of extensive chronic GVHD in recip-
ients of unrelated SCT after the administration of 7.5
or 15 mg/kg THY, with the last dose infused on day
3 or 2 [7]. The patients receiving 15 mg/kg THY
also had the lowest incidence of severe acute GVHD,
not translating into a survival beneﬁt because of a high
rate of fatal infections [7].
Despite the use of 25 mg/kg THY, we did not
observe a high incidence of relapse. We hypothesize
that the early discontinuation of cyclosporine and my-
cophenolate mofetil posttransplant may have contrib-
uted for the emergence of controllable GVHDwith the
development of a graft-versus-leukemia effect, thus com-
pensating for the early in vivo donor T cell depletion
mediated by THY. Overall, this translated into a survival
beneﬁt for the patients with chronic GVHD.
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Bortezomib after
Allografting in Multiple
Myeloma: Association
between Neurotoxicity
and Cyclosporine
Treatment
Relapse following allografting in patients with
multiple myeloma (MM) remains relatively high
[1,2]. The observations of a possible pivotal role of
NF-B in graft-versus-host disease and the efﬁcacy
of bortezomib in refractory/relapsed MM through
the inhibition of NF-B have provided the rationale
for using this new agent in relapsed MM following
allografting [3-9]. We focused on bortezomib-in-
duced neurotoxicity in 24 relapsed patients following
nonmyeloablative/reduced intensity allografting. Nine-
teen were partly described in an earlier report in the
Haematologica/Hematology Journal [8]. Conditioning
regimens were 2 Gy total body irradiation (TBI) based
(n  19) or a combination of thiotepa, cyclophosph-
amide, and melphalan (n  5) [1,8]. Donors were
human leukocyte antigen (HLA) identical siblings
(n  22) or unrelated (n  2). Postgrafting immuno-
suppression consisted of cyclosporine with mycophe-
nolate mofetil or methotrexate. Bortezomib was ad-
ministered after a median of 20 months from
allografting (range 5-54), at ﬁrst (n  6) or second
relapse (n  10), or beyond second relapse (n  8).
Patients received bortezomib 1.0 (n 8) or 1.3 mg/m2
(n  16) on days 1, 4, 8, and 11 every 3 weeks for a
median of 3 courses (1-8), alone (n  5) or in combi-
nation with steroids (n  19). Informed consent was
obtained on enrollment according to the institutional
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